Incidence and risk factors for developing chemotherapy-induced neuropathic pain in 500 cancer patients: A file-based observational study.
Andreas A ArgyriouJordi BrunaFoteini KalofonouRoser VelascoPantelis LitsardopoulosMontse AlemanyGarifallia G AnastopoulouHaralabos P KalofonosPublished in: Journal of the peripheral nervous system : JPNS (2024)
The incidence of CINP in our cohort was comparable to previous reports, with severities fluctuating upwards during chemotherapy and declined post-chemotherapy. Uncomplicated diabetes, the combined paclitaxel plus cisplatin treatment and the increased severity of acute oxaliplatin neurotoxicity mostly increase the risk for developing CINP. OXA-treated patients present less possibilities to recover from CINP after chemotherapy discontinuation, than other chemotherapies.
Keyphrases
- chemotherapy induced
- neuropathic pain
- locally advanced
- newly diagnosed
- spinal cord
- spinal cord injury
- end stage renal disease
- ejection fraction
- type diabetes
- risk factors
- liver failure
- prognostic factors
- squamous cell carcinoma
- respiratory failure
- acinetobacter baumannii
- adipose tissue
- patient reported outcomes
- combination therapy
- metabolic syndrome
- cystic fibrosis
- hepatitis b virus
- drug resistant
- smoking cessation
- adverse drug